Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

WeightWatchers has filed for bankruptcy in the US as it struggles with debt and fierce competition from fat-loss jabs like ...

The legal process will see $1.15bn (£860mn) of the 60-year-old diet brand's debt written off while it agrees new terms for ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Weight Watchers, the brand built on providing support for people who are trying to lose weight, filed for bankruptcy protection. The company is burdened with debt as more customers turn to medication.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

As we learn more about GLP-1 drugs like Wegovy and Zepbound, early research suggests that they may be able to improve COPD ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.